Crinetics Pharmaceuticals Inc CRNX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CRNX is a good fit for your portfolio.
News
-
Crinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients
-
Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome
-
Crinetics Pharmaceuticals Announces March 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
-
Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement
-
Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
-
Crinetics Pharmaceuticals Announces February 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Trading Information
- Previous Close Price
- $42.29
- Day Range
- $41.66–42.87
- 52-Week Range
- $15.76–49.58
- Bid/Ask
- $40.74 / $43.42
- Market Cap
- $3.28 Bil
- Volume/Avg
- 563,205 / 819,020
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 639.90
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 210
- Website
- https://www.crinetics.com
Comparables
Valuation
|
Metric
|
CRNX
|
PNT
|
PMVP
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 11.36 | — |
Price/Book Value | 5.59 | 3.12 | 0.39 |
Price/Sales | 639.90 | 5.50 | — |
Price/Cash Flow | — | 13.90 | — |
Price/Earnings
CRNX
PNT
PMVP
Financial Strength
|
Metric
|
CRNX
|
PNT
|
PMVP
|
|---|---|---|---|
Quick Ratio | 12.92 | 9.01 | 14.47 |
Current Ratio | 13.07 | 9.14 | 14.78 |
Interest Coverage | — | — | — |
Quick Ratio
CRNX
PNT
PMVP
Profitability
|
Metric
|
CRNX
|
PNT
|
PMVP
|
|---|---|---|---|
Return on Assets (Normalized) | −38.81% | 20.67% | −23.12% |
Return on Equity (Normalized) | −44.79% | 23.56% | −25.57% |
Return on Invested Capital (Normalized) | −45.62% | 23.38% | −27.79% |
Return on Assets
CRNX
PNT
PMVP
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Pkcsgfbzv | Dkqrr | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Nbqnwwd | Ymvqqf | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Qybrzrbr | Lwysc | $97.8 Bil | |
MRNA
| Moderna Inc | Wkvrqpjpk | Dndl | $38.8 Bil | |
ARGX
| argenx SE ADR | Stmhdzrrb | Kpkxd | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Ydbdtyz | Kgq | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Bswfdzbt | Mctjts | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Gcylmryv | Dtggsbl | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Fhxdzqyly | Nkxtpb | $12.5 Bil | |
INCY
| Incyte Corp | Wxvxkyj | Xktgn | $11.5 Bil |